Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left ventricular hypertrophy regression: the LIVE trial.

D J Sheridan1

  • 1Academic Cardiology Unit, Division of NHLI, Imperial College School of Medicine, St Mary's Hospital, Queen Elizabeth the Queen Mother Wing, London W2 1NY, UK.

Cardiologia (Rome, Italy)
|December 25, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urinary erythropoietin levels in normal, anaemic, polycythaemic, and uraemic subjects.

Irish journal of medical science·2016
Same author

Reforming research in the NHS.

BMJ (Clinical research ed.)·2005
Same author

Investigation of the effects of physiological and vasodilation-induced autonomic activation on the QTc Interval in healthy male subjects.

British journal of clinical pharmacology·2005
Same author

Endogenous, local, vascular endothelial growth factor production in patients with chronic total coronary artery occlusions: further evidence for its role in angiogenesis.

Heart (British Cardiac Society)·2002
Same author

The action of isoprenaline on the electrophysiological properties of hypertrophied left ventricular myocytes.

Archives of physiology and biochemistry·2002
Same author

Reduced anisotropy of action potential conduction in left ventricular hypertrophy.

Journal of cardiovascular electrophysiology·2001
Same journal

[Prevention in coronary postangioplasty restenosis with omega-3 fatty acids. Results of the Italian study on prevention of restenosis with esapent (ESPRIT)].

Cardiologia (Rome, Italy)·2002
Same journal

[Results of GISSI Prevenzione: diet, drugs, and cardiovascular risk. Researchers of GISSI Prevenzione].

Cardiologia (Rome, Italy)·2002
Same journal

[New therapeutic strategies in heart failure. Which patients need defibrillation backup?].

Cardiologia (Rome, Italy)·2002
Same journal

[Electromechanical re-synchronization with sequential heart stimulation as a new non-pharmacologic treatment of advanced heart failure. Physiopathologic features and clinical results].

Cardiologia (Rome, Italy)·2002
Same journal

[New therapeutic strategies in heart failure. Pharmacologic therapy].

Cardiologia (Rome, Italy)·2002
Same journal

[Genetics as a guide for antihypertensive therapy: future perspectives].

Cardiologia (Rome, Italy)·2002
See all related articles

The LIVE study found that indapamide effectively reduced left ventricular hypertrophy (LVH) in hypertensive patients over one year. This diuretic demonstrated efficacy comparable to enalapril in LVH regression.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Left ventricular hypertrophy (LVH) increases vascular event risk.
  • Diuretic efficacy for LVH reduction is debated.
  • Antihypertensive treatments are evaluated for LVH regression.

Purpose of the Study:

  • To compare indapamide versus enalapril for LVH regression in hypertensive patients.
  • To assess the efficacy of indapamide 1.5 mg daily and enalapril 20 mg daily.
  • To evaluate LVH reduction after one year of treatment.

Main Methods:

  • Prospective, double-blind, randomized controlled trial (LIVE study).
  • Inclusion criteria: Hypertensive patients with LVH.
  • Echocardiography used for LVH assessment, with blind reading by an independent committee.

Related Experiment Videos

Main Results:

  • Preliminary data confirm indapamide's antihypertensive efficacy.
  • Indapamide showed efficacy in reducing left ventricular mass.
  • Progressive LVH reduction observed over one year with indapamide.

Conclusions:

  • Indapamide is effective in reducing left ventricular hypertrophy in hypertensive patients.
  • The study provides evidence for indapamide's role in managing LVH.
  • Indapamide offers a viable treatment option for hypertensive patients with LVH.